Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement

Tian, Chen; Yang, Hongliang; Zhu, Lihong; Zhang, Qing; Cao, Zhen-Dong; Zhang, Yizhuo

doi:10.1007/s00277-017-3029-3

Cited by 22 publications

(13 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, CD138 is an important marker in quantitation of the plasma cell population. Recently, anti-CD138 chimeric antigen receptor-modified T-cell treatment for MM has been reported [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Correlation between baseline 18F-FDG PET/CT findings and CD38, CD138 expressing myeloma cells in bone marrow and clinical parameters in patiens with multiple myeloma

Cengiz

Arda

Doger

et al. 2018

Tjh

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to evaluate the relation between the rate of fluorine-18 (18F) fludeoxyglucose (FDG) uptake and CD38 and CD138 expression in myeloma cells in bone marrow and other clinical parameters in patients with multiple myeloma (MM).Materials and MethodsPatients with the diagnosis of MM who underwent 18F-FDG positron emission tomography/computed tomography (PET/CT) for initial staging were evaluated retrospectively. We analyzed a total of 42 patients (43-83 years old, mean: 64.4±9.9). Hematological and biochemical tests including hemoglobin, hematocrit, C-reactive protein, β2-microglobulin, creatinine, albumin, calcium, lactate dehydrogenase, and erythrocyte sedimentation rate were recorded. In bone marrow samples, plasma cell ratio and CD38 and CD138 immunohistochemical staining were evaluated. On PET/CT images, mean standardized uptake values (SUVmean) of the right anterior and posterior iliac crest and right proximal femora were calculated. The correlations between the average SUVmean of bone marrow and CD38- and CD138-expressing myeloma cells and other parameters were analyzed by Spearman’s correlation test. Values of p<0.05 were considered statistically significant.ResultsTypes of MM were IgGK (45%), IgGL (21%), IgAK (7%), IgAL (10%), and others (17%). Thirty-two (76%) patients were at stage III according to the Salmon-Durie staging system. There was a statistically significant positive correlation between bone marrow FDG uptake and percentage of plasma cells in bone marrow and CD38 and CD138 expression in plasma cells (r=0.403, r=0.339, and r=0.409) and β2-microglobulin and C-reactive protein levels (r=0.676, r=0.541). There was a negative correlation between bone marrow FDG uptake and hemoglobin and hematocrit values (r=-0.377 and r=-0.368). Other hematological parameters were not correlated with FDG uptake in bone marrow.ConclusionIncreased FDG uptake is correlated with the percentage of CD38 and CD138 expression in plasma cells in bone marrow. In addition to initial staging, 18F-FDG PET/CT is useful in treatment planning and prognostic evaluation in MM patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation between baseline 18F-FDG PET/CT findings and CD38, CD138 expressing myeloma cells in bone marrow and clinical parameters in patiens with multiple myeloma

Cengiz

Arda

Doger

et al. 2018

Tjh

View full text Add to dashboard Cite

show abstract

“…CD138 is highly expressed in NDMM and RRMM where it promotes tumor growth (101). Although CD138 is broadly expressed in human tissues, CD138 targeting CAR T-cell therapy reportedly favorable toxicity profile but only modest anti-MM efficacy (9,102). Moreover, immune escape by antigen loss has been reported (103).…”

Section: Cd138mentioning

confidence: 99%

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions

et al. 2020

View full text Add to dashboard Cite

Despite recent therapeutic advances, the prognosis of multiple myeloma (MM) patients remains poor. Thus, new strategies to improve outcomes are imperative. Chimeric antigen receptor (CAR) T-cell therapy has changed the treatment landscape of B-cell malignancies, providing a potentially curative option for patients who are refractory to standard treatment. Long-term remissions achieved in patients with acute lymphoblastic leukemia and Non-Hodgkin Lymphoma encouraged its further development in MM. B-cell maturation antigen (BCMA)-targeted CAR T-cells have established outstanding results in heavily pre-treated patients. However, several other antigens such as SLAMF7 and CD44v6 are currently under investigation with promising results. Idecabtagene vicleucel is expected to be approved soon for clinical use. Unfortunately, relapses after CAR T-cell infusion have been reported. Hence, understanding the underlying mechanisms of resistance is essential to promote prevention strategies and to enhance CAR T-cell efficacy. In this review we provide an update of the most recent clinical and pre-clinical data and we elucidate both, the potential and the challenges of CAR T-cell therapy in the future.

show abstract

“…With extramedullary involvement, this patient achieved PR. 56 In addition, some original preclinical studies on novel targets, such as CD38 (with 13 registered CAR T clinical trials), 57 CD123 (with 18 registered CAR T clinical trials), 58,59 CD4 (with 3 registered CAR T clinical trials), 60 and CD7 (with 3 registered CAR T clinical trials) 61 have also been reported. We believe that in the future, more CAR T clinical studies for different hematological tumors will be reported.…”

Section: Bcmamentioning

confidence: 99%

Clinical development of CAR T cell therapy in China: 2020 update

et al. 2020

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in the treatment of hematological malignancies. In recent years, fast-growing CAR T clinical trials have actively explored their potential application scenarios. According to the data from the clinicaltrials.gov website, China became the country with the most registered CAR T trials in September 2017. As of June 30, 2020, the number of registered CAR T trials in China has reached 357. In addition, as many as 150 other CAR T trials have been registered on ChiCTR. Although CAR T therapy is flourishing in China, there are still some problems that cannot be ignored. In this review, we aim to systematically summarize the clinical practice of CAR T-cell therapy in China. This review will provide an informative reference for colleagues in the field, and a better understanding of the history and current situation will help us more reasonably conduct research and promote cooperation.

show abstract

Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement

Cited by 22 publications

References 4 publications

Correlation between baseline 18F-FDG PET/CT findings and CD38, CD138 expressing myeloma cells in bone marrow and clinical parameters in patiens with multiple myeloma

Correlation between baseline 18F-FDG PET/CT findings and CD38, CD138 expressing myeloma cells in bone marrow and clinical parameters in patiens with multiple myeloma

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions

Clinical development of CAR T cell therapy in China: 2020 update

Contact Info

Product

Resources

About